Log in to save to my catalogue

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1549199078

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

Publication information

Publisher

Kidlington: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Etrolizumab is a humanised monoclonal antibody that selectively binds the β7 subunit of the heterodimeric integrins α4β7 and αEβ7. We aimed to assess etrolizumab in patients with moderately-to-severely active ulcerative colitis. Methods In this double-blind, placebo-controlled, randomised, phase 2 study, patients with moderately-...

Alternative Titles

Full title

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1549199078

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1549199078

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(14)60661-9

How to access this item